HCW Biologics (NASDAQ:HCWB) Rating Lowered to “Sell” at Wall Street Zen

HCW Biologics (NASDAQ:HCWB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Price Performance

Shares of NASDAQ HCWB opened at $1.60 on Friday. The firm’s 50-day moving average is $2.45 and its two-hundred day moving average is $4.19. The company has a market capitalization of $3.58 million, a PE ratio of -0.06 and a beta of 2.41. HCW Biologics has a 12-month low of $1.50 and a 12-month high of $27.57.

HCW Biologics (NASDAQ:HCWB) last issued its quarterly earnings data on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%. The business had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.14 million.

HCW Biologics Company Profile

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases.

HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic.